Welcome to our dedicated page for Cyclacel Pharma news (Ticker: CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharma stock.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company whose news flow centers on cancer drug development, capital markets activity and strategic transactions. The company publicly describes its focus as developing cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, with its lead candidate plogosertib, a PLK1 inhibitor, being evaluated in patients with solid tumors and hematological malignancies.
News updates for CYCC often include clinical and preclinical developments related to plogosertib. Cyclacel has highlighted independent studies showing that biliary tract cancer and fibrolamellar hepatocellular carcinoma cells can be sensitive to PLK1 inhibition with plogosertib, as well as early Phase 1 data where oral plogosertib was reported to be well tolerated without dose-limiting toxicity in several dosing schedules. These items give investors and researchers insight into how external and internal data may shape the company’s oncology pipeline.
Cyclacel’s news also covers financial results and funding events, such as quarterly earnings updates, private placements of convertible preferred stock with accompanying warrants, and declarations of quarterly cash dividends on its 6% Convertible Exchangeable Preferred Stock. In addition, the company has issued releases on Nasdaq listing matters, including notices about minimum bid price compliance and announcements of reverse stock splits that affect the share structure while maintaining the CYCC ticker on The Nasdaq Capital Market.
Another recurring theme in Cyclacel news is strategic alternatives and corporate transactions. The company has discussed evaluating options to continue as a going concern and has announced an Exchange Agreement to acquire Fitters Sdn. Bhd., a Malaysia-based fire safety and protective equipment business, in a share and cash transaction subject to approvals. For investors tracking CYCC, following these news items helps monitor both the scientific progress of plogosertib and the company’s evolving capital structure and business direction.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced its participation in two upcoming investor conferences. The Oppenheimer 33rd Annual Healthcare Conference will be held virtually from March 13-15, 2023, featuring a fireside chat on March 13 at 10:00 am ET led by Spiro Rombotis. The 35th Annual Roth Conference takes place in Dana Point, CA from March 12-14, 2023, with a fireside chat on March 13 at 3:00 pm PT presented by Paul McBarron. Cyclacel is focused on developing innovative cancer treatments targeting cell cycle and transcriptional regulation.
Cyclacel Pharmaceuticals reported its 2022 financial results and outlined key objectives for 2023. The company aims to advance oral fadraciclib into Phase 2 trials and explore the potential of oral plogosertib. They anticipate multiple data readouts including interim results from their Phase 1/2 studies. As of December 31, 2022, cash and equivalents were $18.3 million, down from $36.6 million in 2021, with a net loss of $21.2 million. R&D expenses rose due to ongoing trials for both drug candidates. The company believes it can fund operations through the fourth quarter of 2023.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) is set to announce its fourth quarter and full year 2022 financial results on March 6, 2023, at 4:30 PM ET. Following the announcement, a conference call will be hosted to discuss the results and company updates. Investors can access the call via toll-free numbers or webcasts. Cyclacel focuses on developing innovative cancer therapies, including the CDK2/9 inhibitor fadraciclib and the PLK1 inhibitor plogosertib. The company’s strategy aims to establish a diversified pipeline addressing oncology and hematology indications.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will present an overview of its business and clinical programs at the BIO CEO & Investor Conference on February 6-9, 2023. CEO Spiro Rombotis is scheduled to speak on February 6 at 9:30 AM ET in the Music Box room at the New York Marriott Marquis Times Square. The Company, focused on developing innovative cancer treatments, is available for meetings with attendees through the BIO One-on-One Partnering system. Cyclacel is advancing multiple drug candidates, including fadraciclib and plogosertib, targeting oncology and hematology indications. For more information, visit cyclacel.com.
Cyclacel Pharmaceuticals (CYCC, CYCCP) has made significant strides in 2022, focusing on its two leading drug candidates, fadraciclib and plogosertib, which are in Phase 1/2 clinical studies. The company anticipates starting Phase 2 trials for fadraciclib in 1Q 2023, following promising early results including 2/3 partial responses in T-cell lymphoma. With sufficient cash reserves projected to last through 2023, Cyclacel expects key data readouts this year, providing further insight into both drugs' efficacy and safety.
Cyclacel Pharmaceuticals plans to present at the Biotech Showcase and host meetings at a Corporate Access Event from January 9-11, 2023, in San Francisco. Spiro Rombotis, CEO, and Paul McBarron, EVP, will discuss the company's clinical advancements and goals. The Biotech Showcase presentation is on January 10 at 9:30 am PT at Hilton San Francisco Union Square. Cyclacel focuses on cancer therapies, particularly fadraciclib and CYC140, addressing solid tumors and hematological malignancies. For more details, visit www.cyclacel.com.
FAQ
What is the current stock price of Cyclacel Pharma (CYCC)?
What is the market cap of Cyclacel Pharma (CYCC)?
